Peri-operative SARS-CoV-2 infection increases postoperative mortality. The aim of this study was to determine the optimal duration of planned delay before surgery in patients who have had SARS-CoV-2 infection. This international, multicentre, prospective cohort study included patients undergoing elective or emergency surgery during October 2020. Surgical patients with pre-operative SARS-CoV-2 infection were compared with those without previous SARS-CoV-2 infection. The primary outcome measure was 30-day postoperative mortality. Logistic regression models were used to calculate adjusted 30-day mortality rates stratified by time from diagnosis of SARS-CoV-2 infection to surgery. Among 140,231 patients (116 countries), 3127 patients (2.2%) had a pre-operative SARS-CoV-2 diagnosis. Adjusted 30-day mortality in patients without SARS-CoV-2 infection was 1.5% (95%CI 1.4-1.5). In patients with a pre-operative SARS-CoV-2 diagnosis, mortality was increased in patients having surgery within 0-2 weeks, 3-4 weeks and 5-6 weeks of the diagnosis (odds ratio (95%CI) 4.1 (3.3-4.8), 3.9 (2.6-5.1) and 3.6 (2.0-5.2), respectively). Surgery performed ≥ 7 weeks after SARS-CoV-2 diagnosis was associated with a similar mortality risk to baseline (odds ratio (95%CI) 1.5 (0.9-2.1)). After a ≥ 7 week delay in undertaking surgery following SARS-CoV-2 infection, patients with ongoing symptoms had a higher mortality than patients whose symptoms had resolved or who had been asymptomatic (6.0% (95%CI 3.2-8.7) vs. 2.4% (95%CI 1.4-3.4) vs. 1.3% (95%CI 0.6-2.0), respectively). Where possible, surgery should be delayed for at least 7 weeks following SARS-CoV-2 infection. Patients with ongoing symptoms ≥ 7 weeks from diagnosis may benefit from further delay.
The astrophysical s-process is one of the two main processes forming elements heavier than iron. A key outstanding uncertainty surrounding s-process nucleosynthesis is the neutron flux generated by the 22 Ne(α, n) 25 Mg reaction during the He-core and C-shell burning phases of massive stars. This reaction, as well as the competing 22 Ne(α, γ) 26 Mg reaction, is not well constrained in the important temperature regime from ∼0.2-0.4 GK, owing to uncertainties in the nuclear properties of resonances lying within the Gamow window. To address these uncertainties, we have performed a new measurement of the 22 Ne( 6 Li, d) 26 Mg reaction in inverse kinematics, detecting the outgoing deuterons and 25,26 Mg recoils in coincidence. We have established a new n/γ decay branching ratio of 1.14(26) for the key E x = 11.32 MeV resonance in 26 Mg, which results in a new (α, n) strength for this resonance of 42(11) µeV when combined with the well-established (α, γ) strength of this resonance. We have also determined new upper limits on the α partial widths of neutron-unbound resonances at E x = 11. 112, 11.163, 11.169, and 11.171 MeV. Monte-Carlo calculations of the stellar 22 Ne(α, n) 25 Mg and 22 Ne(α, γ) 26 Mg rates, which incorporate these results, indicate that both rates are substantially lower than previously thought in the temperature range from ∼0.2-0.4 GK.
The 22 Ne(α, n) reaction is expected to provide the dominant neutron source for the weak s process in massive stars and intermediate-mass (IM) Asymptotic Giant Branch (AGB) stars. However, the production of neutrons in such environments is hindered by the competing 22 Ne(α, γ) 26 Mg reaction. Here, the 11 B(16 O,p) fusion-evaporation reaction was used to identify γ-decay transitions from 22 Ne + α resonant states in 26 Mg. Spin-parity restrictions have been placed on a number of α-unbound excited states in 26 Mg and their role in the 22 Ne(α, γ) 26 Mg reaction has been investigated. In particular, a suspected natural-parity resonance at E c.m. = 557(3) keV, that lies above the neutron threshold in 26 Mg, and is known to exhibit a strong α-cluster character, was observed to γ decay. Furthermore, a known resonance at E c.m. = 466(4) keV has been definitively assigned 2 + spin and parity. Consequently, uncertainties in the 22 Ne(α, γ) stellar reaction rate have been reduced by a factor of ∼ 20 for temperatures ∼ 0.2 GK.
In Wolf-Rayet and asymptotic giant branch (AGB) stars, the 26g Alðp; γÞ 27 Si reaction is expected to govern the destruction of the cosmic γ-ray emitting nucleus 26 Al. The rate of this reaction, however, is highly uncertain due to the unknown properties of key resonances in the temperature regime of hydrogen burning. We present a high-resolution inverse kinematic study of the 26g Alðd; pÞ 27 Al reaction as a method for constraining the strengths of key astrophysical resonances in the 26g Alðp; γÞ 27 Si reaction. In particular, the results indicate that the resonance at E r ¼ 127 keV in 27 Si determines the entire 26g Alðp; γÞ 27 Si reaction rate over almost the complete temperature range of Wolf-Rayet stars and AGB stars.
We report the first observation of the 108 Xe → 104 Te → 100 Sn α-decay chain. The α emitters, 108 Xe [Eα = 4.4(2) MeV, T1 /2 = 58 +106 −23 µs] and 104 Te [Eα = 4.9(2) MeV, T1 /2 <18 ns], decaying into doubly magic 100 Sn were produced using a fusion-evaporation reaction 54 Fe(58 Ni,4n) 108 Xe, and identified with a recoil mass separator and an implantation-decay correlation technique. This is the first time α radioactivity has been observed to a heavy self-conjugate nucleus. A previous benchmark for study of this fundamental decay mode has been the decay of 212 Po into doubly magic 208 Pb. Enhanced proton-neutron interactions in the N = Z parent nuclei may result in superallowed α decays with reduced α-decay widths significantly greater than that for 212 Po. From the decay chain, we deduce that the α-reduced width for 108 Xe or 104 Te is more than a factor of 5 larger than that for 212 Po.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.